DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Consensus Recommendation of “Hold” by Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have received a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company.

Several brokerages have commented on DSRLF. UBS Group cut shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Piper Sandler started coverage on shares of DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Finally, Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research report on Tuesday, May 12th.

DiaSorin Stock Up 9.1%

Shares of DSRLF stock opened at $81.00 on Friday. The business’s fifty day moving average price is $73.79 and its 200 day moving average price is $75.95. DiaSorin has a 1-year low of $66.50 and a 1-year high of $100.00.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.